Marriage Counselors in Searcy, AR Accepting Medicare

6 Marriage Counselors found. Showing 1 - 6

Nicole Brown, LPC, LMFT Marriage & Family Therapist Medicare: Medicare Enrolled Practice Location: 406 Rodgers Dr, Searcy, AR 72143 Phone: 501-279-7979

Mr. Cale E Mcgillvray, LPC, LMFT Marriage & Family Therapist Medicare: Medicare Enrolled Practice Location: 1507 E. Race St., Searcy, AR 72143 Phone: 501-305-2359    Fax: 501-305-2348

Joe Stephen Brumfield, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 2908 Hawkins Dr, Searcy, AR 72143 Phone: 501-203-0055    Fax: 501-203-0060

Jeremy Shelby, LPC, LAMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 106 S Spring St, Searcy, AR 72143 Phone: 501-279-1191    Fax: 501-313-0032

James Edward Roesch, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 915 E Beebe Capps Expy, Searcy, AR 72143 Phone: 501-729-1700    Fax: 501-391-3090

Mrs. Kelsey Ann Bennett Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 306 S Charles St Apt 6, Searcy, AR 72143 Phone: 352-223-5436

News Archive

Guidance for Quick-Med Technologies' NIMBUS barrier gauze wound dressings issued

Quick-Med Technologies, Inc. announced today that the Food and Drug Administration has issued Guidance to support the classification of the Company's NIMBUS® barrier gauze wound dressings as Class II medical devices.

Study finds disagreement between RA patients and doctors on assessment of disease severity

A novel study by researchers at the University of California, San Francisco found that nearly one-third of Rheumatoid Arthritis (RA) patients differed from their physicians in assessment of their disease severity. The disagreement between patient and doctor evaluation of RA activity was most prevalent in patients with depressive symptoms, and those who had poor overall function.

InteRNA, Silence partner to develop novel microRNA therapeutics for cancer

Silence Therapeutics plc, a leading global RNA interference (RNAi) therapeutics company, and InteRNA Technologies B.V., a biopharmaceutical company developing pathway targeted microRNA-based therapeutics for cancer, today announce that they have entered into an agreement to develop novel microRNA therapeutics for the treatment of cancer.

Dexmedetomidine may be an effective treatment option for opioid-induced hyperalgesia

Surgical patients who demonstrated heightened pain sensitivity, or hyperalgesia, induced by high doses of a synthetic opioid had their symptoms alleviated by co-treatment with dexmedetomidine, according to new research. Study investigators, who presented their results today at the 29th Annual Meeting of the American Academy of Pain Medicine, concluded that dexmedetomidine may be a new and effective treatment option for opioid-induced hyperalgesia (OIH).

Read more Medical News

› Verified 2 days ago